European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis

Descripción del proyecto

Programa de formación en investigación para el tratamiento de pacientes con nefropatías terminales

La diálisis peritoneal (DP o PD, por sus siglas en inglés) es un tratamiento de sustitución renal que salva la vida de los pacientes que padecen una nefropatía terminal. Existe una necesidad urgente de contar con enfoques individualizados para la DP, ya que estos pacientes tienen un mayor riesgo de padecer enfermedades cardiovasculares relacionadas con una elevada mortalidad. Financiado por las Acciones Marie Skłodowska-Curie, el proyecto IMPROVE-PD tiene por objeto involucrar a los principales investigadores universitarios e industriales en la creación de una plataforma de formación para comprender los mecanismos de las enfermedades cardiovasculares inflamatorias en pacientes de DP y desarrollar tratamientos individualizados para las personas que están en riesgo. El objetivo es formar a quince jóvenes científicos que van a trabajar en un programa europeo multidisciplinar de formación de nivel de doctorado que incluye a destacados socios universitarios, clínicos e industriales.

Objetivo

Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. There is an unmet need for a risk-adjusted individualized PD approach. The IMPROVE-PD consortium provides 15 Early Stage Researchers (ESRs) in 11 partner institutes located in 7 different countries a state-of-the-art, multidisciplinary and intersectoral pan- European training programme including input from academic, clinical and industrial stakeholders. Network-wide and local training activities, individual research projects, intersectoral secondments and short laboratory visits will provide key generic skills and will prepare ESRs for future roles as highly skilled researchers in Europe. Well-phenotyped patient cohorts, and novel experimental models and techniques will be exploited by the ESRs, mentored by an excellent supervisory team, to improve future management of the PD patient at risk. This joint effort encourages productive collaboration between industrial and academic sectors though integrated projects and shared goals. Key findings will be communicated to a broad range of stakeholders through state of the art methods. IMPROVE-PD will give rise to a new generation of experts in PD with outstanding interdisciplinary research skills, intersectoral understanding and with perspective to pursue their careers in this scientific and industrial field. It will enable timely identification of the PD patient at high risk for adverse outcome, develop understanding of underlying pathomechanisms, and within an iterative process between research groups foster the development of innovative approaches to individualized treatment by targeting revealed pathomechanisms. Through these approaches, the ITN will achieve refinement of PD fluids, PD therapy and cardiovascular risk reduction.

Coordinador

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Aportación neta de la UEn
€ 501 809,76
Dirección
CALLE SERRANO 117
28006 Madrid
España

Ver en el mapa

Región
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 501 809,76

Participantes (11)

Socios (11)